SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune ...

Alumis has reached significant milestones recently, including the release of 52-week Phase II Open-Label Extension (OLE) data for ESK-001, an oral TYK2 inhibitor used in the treatment of psoriasis.

Even the CEOs of Big Pharmas have come under fire. Activist investor Starboard Value has made no secret of its criticism of Pfizer CEO Albert Bourla’s track record, while GSK CEO Emma Walmsley fought ...

Financial advisory services for the merger were provided by Morgan Stanley (NYSE: MS) & Co. LLC and Guggenheim Securities, LLC, with legal counsel from Cooley LLP, Fenwick & West LLP, and Paul ...

Alumis Inc (Symbol: ALMS) saw options trading volume of 4,858 contracts, representing approximately 485,800 underlying shares or approximately 43% of ALMS's average daily trading volume over the ...

Alumis has concluded enrolment in its pivotal Phase III ONWARD programme, aimed to assess the safety and efficacy of the oral tyrosine kinase 2 (TYK2) inhibitor, ESK-001, for treating adults with ...

On Monday, Morgan Stanley resumed its coverage of Alumis Inc. (NASDAQ:ALMS) with an Overweight rating and a $23 price target after the company’s recent merger with Acelyrin and its Q1 2025 ...

Nasdaq Listed Alerts Market: Pre-Market Alumis Inc. Common Stock (ALMS) Bid: $3.30 X 1697 Ask: $3.91 X 100 Volume: 58 ...

Kim Winters Alumis said: "I like how parks and green spaces have patches of longer grass. It looks much better then just boring short grass." Follow Daily Record: Facebook X (Twitter) Instagram ‌ ...

Find the latest Alumis Inc. (ALMS) stock quote, history, news and other vital information to help you with your stock trading and investing.